NCT04012060: LIAR

Patient Reported Health-Related Quality of Life After Limited Access and Conventional Aortic Valve Replacement

Completed NA Last updated 13 May 2021

What this trial tests

NA trial testing Limited access aortic valve replacement. in Aortic Valve Stenosis in 161 participants. Completed in 7 July 2020.

Timeline

13 June 2016

Primary endpoint
7 July 2020

7 July 2020

Quick facts

Lead sponsor	St. Antonius Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	161
Start date	13 June 2016
Primary completion	7 July 2020
Estimated completion	7 July 2020
Sites	1 location across Netherlands

Drugs / interventions tested

• Limited access aortic valve replacement.
• Conventional aortic valve replacement

Conditions studied

• Aortic Valve Stenosis — all drugs for Aortic Valve Stenosis →
• Limited Access Aortic Valve Replacement — all drugs for Limited Access Aortic Valve Replacement →
• Quality of Life — all drugs for Quality of Life →

Sponsor

St. Antonius Hospital

Who can join

Eligibility, any sex, with Aortic Valve Stenosis or Limited Access Aortic Valve Replacement. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The LIAR-Trial is a single-center, single blind randomized controlled clinical trial comparing patients undergoing isolated AVR via J-shaped upper hemi-sternotomy (UHS) and conventional AVR through a full median sternotomy (FMS). Primary outcome is cardiac-specific quality of life, measured by two domains of the Kansas City Cardiomyopathy Questionnaire (KCCQ), up to one year after surgery.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Limited versus full sternotomy for aortic valve replacement.
   Kirmani BH, Jones SG, Muir A, Malaisrie SC, et al · · 2023 · cited 13× · PMID 38054555 · DOI 10.1002/14651858.cd011793.pub3
2. Comparing quality of life and postoperative pain after limited access and conventional aortic valve replacement: Design and rationale of the LImited access aortic valve replacement (LIAR) trial.
   Klop IDG, van Putte BP, Kloppenburg GTL, Sprangers MAG, et al · · 2021 · cited 5× · PMID 33506139 · DOI 10.1016/j.conctc.2021.100700
3. Postoperative quality of life and pain after upper hemisternotomy and conventional median sternotomy for aortic valve replacement: results of a randomized clinical trial.
   Klop IDG, Van Putte BP, Kloppenburg GTL, Klautz RJM, et al · · 2024 · cited 4× · PMID 38751044 · DOI 10.1093/icvts/ivae083
4. Five-Year Quality of Life Outcome From a Randomized Controlled Trial Comparing Aortic Valve Replacement Through Upper Hemisternotomy and Full Median Sternotomy.
   van Putten SE, Klop IDG, Nieuwkerk PT, Friguech B, et al · · 2026 · PMID 41627861 · DOI 10.1093/ejcts/ezag077